| All HFpEF (n = 163) | HFpEF with events (n = 26) | HFpEF without events (n = 137) | P-value* |
---|---|---|---|---|
Age, years | 73 ± 9 | 76 ± 8 | 73 ± 8 | 0.078 |
Sex, female | 86 (53%) | 12 (44%) | 74 (54%) | 0.46 |
NYHA class | Â | Â | Â | Â |
 II/III | 163 (100%) | 26 (100%) | 137 (100%) | – |
 IV | 0 (0%) | 0 (0%) | 0 (0%) | – |
Body mass index, kg/m2 | 23.5 ± 3.6 | 23.3 ± 3.7 | 23.6 ± 3.6 | 0.69 |
Heart rate, beats/min | 64 ± 12 | 70 ± 13 | 62 ± 10 | 0.002 |
Systolic blood pressure, mmHg | 135 ± 19 | 138 ± 19 | 134 ± 19 | 0.38 |
Diastolic blood pressure, mmHg | 72 ± 11 | 73 ± 10 | 72 ± 12 | 0.84 |
History of heart failure hospitalization | 56 (34%) | 20 (77%) | 36 (26%) |  < 0.001 |
Smoking | 4 (9%) | 0 (0%) | 4 (3%) | 0.18 |
Hypertension | 99 (61%) | 16 (61%) | 83 (61%) | 0.92 |
Dyslipidemia | 91 (56%) | 14 (58%) | 77 (56%) | 0.82 |
Diabetes mellitus | 41 (25%) | 11 (42%) | 30 (22%) | 0.028 |
Atrial fibrillation | 50 (31%) | 11 (42%) | 39 (28%) | 0.16 |
Medications | Â | Â | Â | Â |
 Aspirin | 97 (60%) | 12 (46%) | 85 (62%) | 0.13 |
 Beta-blockers | 62 (38%) | 6 (23%) | 56 (41%) | 0.087 |
 Calcium channel blockers | 51 (31%) | 5 (19%) | 46 (34%) | 0.15 |
 ACE inhibitors/ARBs | 66 (41%) | 10 (38%) | 56 (41%) | 0.81 |
 Statins | 85 (52%) | 12 (46%) | 73 (53%) | 0.51 |
 Diuretics | 18 (11%) | 5 (19%) | 13 (9%) | 0.15 |
Blood tests | Â | Â | Â | Â |
 Hemoglobin, g/dL | 13.3 ± 1.3 | 13.2 ± 1.3 | 13.4 ± 1.3 | 0.69 |
 eGFR, mL/min/1.73 m2 | 62 ± 13 | 55 ± 14 | 63 ± 13 | 0.008 |
 BNP, pg/mL | 114 ± 80 | 139 ± 110 | 109 ± 72 | 0.077 |
Echocardiography | Â | Â | Â | Â |
 E/e’ | 14.4 ± 6.2 | 15.8 ± 10.7 | 14.2 ± 5.0 | 0.24 |
 Left atrial volume index, ml/m2 | 40 ± 15 | 49 ± 26 | 38 ± 12 | 0.003 |